Comparative Pharmacology
Head-to-head clinical analysis: DEPACON versus ZTALMY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPACON versus ZTALMY.
DEPACON vs ZTALMY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Ganaxolone is a positive allosteric modulator of GABAA receptors, acting at extrasynaptic and synaptic receptors to enhance chloride ion conductance and inhibit neuronal excitability.
10-15 mg/kg/day IV or orally divided every 8 hours; maximum 60 mg/kg/day.
Initial: 5 mg orally once daily for 7 days; titrate by 5 mg/day every 7 days to a maintenance dose of 30 mg once daily. Maximum: 30 mg daily.
None Documented
None Documented
10–16 hours; neonates 20–30 hours; patients with liver disease up to 18 hours; decreased half-life in patients on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) to 4–9 hours.
Terminal elimination half-life is approximately 30 hours (range 20-40 hours) in adults, supporting once-daily dosing. Steady-state is achieved within 5-7 days.
Primarily renal: >90% of a dose is excreted in urine as valproic acid glucuronide (30–50%), 3-oxo-valproic acid (30–40%), and other metabolites. Less than 3% excreted unchanged. Minor fecal elimination (≈5%).
Primarily hepatic metabolism via glucuronidation and oxidation; <1% excreted unchanged in urine. Fecal elimination accounts for approximately 90% of the administered dose, with <5% in urine.
Category C
Category C
Anticonvulsant
Anticonvulsant